UNITY BIOTECHNOLOGY INC. news, videos and press releases
For more news please use our advanced search feature.
UNITY BIOTECHNOLOGY INC. - More news...
UNITY BIOTECHNOLOGY INC. - More news...
- UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates
- UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
- UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME
- UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
- UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema
- UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025
- UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors
- UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
- UNITY Biotechnology Reports Granting of New Employment Inducement Award
- UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer
- UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates
- UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024
- UNITY Biotechnology to Participate in Upcoming Investor Conferences
- UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
- UNITY Biotechnology Reports Granting of New Employment Inducement Award
- UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer
- UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
- UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
- UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
- UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
- UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
- UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
- UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
- UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
- UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates
- UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)
- UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
- UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
- UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
